The attached article demonstrates a key role for tumor-derived HSP70 in the development of robust anti-tumor immune responses. The results validate HSP70 as a target for the development of a novel class of immunomodulatory drugs, which is the focus of the Asylia platform.
Published by Oncogene; March 14, 2014
